Floatz logo

Zuberitamab

DLBCL - Diffuse Large B Cell Lymphoma

Ou Bai, MD/PHDPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

270 Active assets in the DLBCL - Diffuse Large B Cell Lymphoma cohort.

Asset / SponsorPhaseRating
VINCRISTINE SULFATE
National Cancer Institute (NCI)
Phase 2/3A
Evomela
Ruijin Hospital
Phase 4BBB
Axicabtagene Ciloleucel
Ruijin Hospital
Phase 4BBB
PREDNISONE TABLETS
Beth Israel Deaconess Medical Center
Phase 4BBB
Inno-206
Beth Israel Deaconess Medical Center
Phase 4BBB

View all 50 →

Same molecule, other indications

Zuberitamab is also rated in:

mantle cell lymphomaDormant
B
Indicative ·
62 / 100
View asset →
marginal zone lymphomaDormant
CCC
Indicative ·
53 / 100
View asset →
Bispecific AntibodyDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →